Werewolf Therapeutics Inc’s recent filing unveils that its Shareholder MPM Asset Management Investors acquired Company’s shares for reported $5867.0 on Nov 04 ’25. In the deal valued at $1.31 per share,4,479 shares were bought.
Then, MPM BioVentures 2014 (B), L.P. bought 8,679 shares, generating $11,369 in total proceeds.
Before that, UBS Oncology Impact Fund, L.P. bought 107,463 shares. Werewolf Therapeutics Inc shares valued at $140,777 were divested by the Shareholder at a price of $1.31 per share.
JMP Securities initiated its Werewolf Therapeutics Inc [HOWL] rating to a Mkt outperform in a research note published on April 03, 2024; the price target was $12. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late August with a ‘”an Outperform”‘ rating. BofA Securities started covering the stock on September 10, 2021. It rated HOWL as “a Buy”.
Price Performance Review of HOWL
On Tuesday, Werewolf Therapeutics Inc [NASDAQ:HOWL] saw its stock fall -7.63% to $1.21. Over the last five days, the stock has lost -25.31%. Werewolf Therapeutics Inc shares have fallen nearly -52.64% since the year began. Nevertheless, the stocks have fallen -18.24% over the past one year. While a 52-week high of $2.52 was reached on 09/29/25, a 52-week low of $0.60 was recorded on 04/07/25.
Levels Of Support And Resistance For HOWL Stock
The 24-hour chart illustrates a support level at 1.1467, which if violated will result in even more drops to 1.0833. On the upside, there is a resistance level at 1.2867. A further resistance level may holdings at 1.3633.
How much short interest is there in Werewolf Therapeutics Inc?
A steep rise in short interest was recorded in Werewolf Therapeutics Inc stocks on 2025-10-15, growing by 1309.0 shares to a total of 0.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 0.82 million shares. There was a rise of 0.16%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 25, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
